Delivery Order SPE2DR25D1007-SPE2DR26FY8JS
- Not listed
- The Defense Logistics Agency awarded a $2,173.01 firm fixed price delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens. The contract, which is a child order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA, requires delivery by October 22, 2025, to the company's distribution facility in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation,...
- The Defense Logistics Agency awarded a $6,644.52 delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens with a completion date of December 2, 2025. The contract is a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency (DLA) awarded a $8,308.62 delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 15 mg/0.5 mL pens on December 8, 2025, with an ultimate completion date of December 9, 2025. This competitively awarded, firm fixed-price contract requires no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the performing location for this pharmaceutical supply delivery. The order represents a single transaction under...
- The Defense Logistics Agency awarded a $1,143.89 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections. The contract, which represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), is scheduled for completion by August 18, 2025. This delivery order was competitively awarded without...
- The Defense Logistics Agency awarded a delivery order valued at $10,128.30 to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound (semaglutide) 12.5 mg/0.5 mL pens. This is a firm fixed-price delivery order with a completion date of August 21, 2025, issued under a competitive procurement with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with...
- The Defense Logistics Agency awarded a delivery order valued at $28,560.25 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pens on November 20, 2025. This is a firm fixed-price delivery order with an ultimate completion date of November 21, 2025, and represents a non-set-aside competitive award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $54,899.82 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 15 mg/0.5 ml pen injections on November 25, 2025, with completion expected by November 26, 2025. This delivery order represents a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract was awarded without...
- The Defense Logistics Agency awarded a $1,143.89 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 12.5 mg/0.5 mL pens on August 7, 2025, with an ultimate completion date of August 8, 2025. The contract was competitively awarded with no set-aside designation and specifies performance at AmerisourceBergen's Conshohocken, Pennsylvania location. This delivery order represents a single transaction under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a $3,558.30 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 2.5 mg/0.5 mL pens on August 15, 2025, with an ultimate completion date of August 18, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a $6,360.82 delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 12.5 mg/0.5 mL pen injections on November 26, 2025, with completion targeted for November 28, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical will...
- SPE2DR25D1007Indefinite Delivery Contract
- SPE2DR25D1007-SPE2DR26FY8JSDelivery Order
The Defense Logistics Agency awarded a $2,214.84 delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 15 mg/0.5 mL pens on December 3, 2025, with an ultimate completion date of December 4, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of the company's pharmaceutical supply relationship with the federal government. The product will be distributed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with the Defense Logistics Agency Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a prime pharmaceutical vendor for the DLA Medical Supply Chain, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military and federal healthcare systems worldwide. The Zepbound order aligns with the company's established portfolio of delivering specialty medications across multiple therapeutic domains to the Defense Health Agency and other federal healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 12/2/25 |